Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)

Ukraine

All drugs from this manufacturer

  • EPLERIK

    The drug is used as an adjunct to standard therapy to reduce the risk of cardiovascular morbidity and mortality in adults with heart failure and impaired left ventricular function (following myocardial infarction or in chronic heart failure).

    Dosage form: tablets, film-coated

    Active substance Dosage
    eplerenone 25 mg

    ATC: C03DA04

  • The drug is used as an adjunct to standard therapy to reduce the risk of cardiovascular morbidity and mortality in patients with heart failure and left ventricular dysfunction (following myocardial infarction or in class II chronic heart failure).

    Dosage form: tablets, film-coated

    Active substance Dosage
    eplerenone 50 mg

    ATC: C03DA04

  • The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2 receptor-negative breast cancer (locally advanced or metastatic). It is used in combination with aromatase inhibitors or in combination with fulvestrant.

    Dosage form: tablets, film-coated

    Active substance Dosage
    palbociclib 75 mg

    ATC: L01EF01

  • The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or in combination with fulvestrant (for women who have previously received endocrine therapy).

    Dosage form: tablets, film-coated

    Active substance Dosage
    palbociclib 100 mg

    ATC: L01EF01

  • The drug is intended for the treatment of hormone receptor-positive (HR-positive) and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or in combination with fulvestrant (for women who have previously received endocrine therapy).

    Dosage form: tablets, film-coated

    Active substance Dosage
    palbociclib 125 mg

    ATC: L01EF01

  • The drug is used to treat functional urinary tract disorders occurring in benign prostatic hyperplasia (enlargement of the prostate gland).

    Dosage form: capsules, modified release, hard

    Active substance Dosage
    tamsulosin 0.4 mg

    ATC: G04CA02

  • The drug is used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (enlargement of the prostate gland).

    Dosage form: tablets, extended-release

    Active substance Dosage
    tamsulosin 0.4 mg

    ATC: G04CA02